[go: up one dir, main page]

DE69726281D1 - Hemmstoff für die gefässneubildung, der den gewebefaktor-inhibitor (tfpi) enthält - Google Patents

Hemmstoff für die gefässneubildung, der den gewebefaktor-inhibitor (tfpi) enthält

Info

Publication number
DE69726281D1
DE69726281D1 DE69726281T DE69726281T DE69726281D1 DE 69726281 D1 DE69726281 D1 DE 69726281D1 DE 69726281 T DE69726281 T DE 69726281T DE 69726281 T DE69726281 T DE 69726281T DE 69726281 D1 DE69726281 D1 DE 69726281D1
Authority
DE
Germany
Prior art keywords
inhibitor
tfpi
tissue factor
vasilizer
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69726281T
Other languages
English (en)
Other versions
DE69726281T2 (de
Inventor
Tsutornu Hamuro
Yo Nakahara
Sumiyo Takemoto
Seiji Miyamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Sero Therapeutic Research Institute Kaketsuken
Original Assignee
Chemo Sero Therapeutic Research Institute Kaketsuken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeutic Research Institute Kaketsuken filed Critical Chemo Sero Therapeutic Research Institute Kaketsuken
Application granted granted Critical
Publication of DE69726281D1 publication Critical patent/DE69726281D1/de
Publication of DE69726281T2 publication Critical patent/DE69726281T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69726281T 1996-03-25 1997-03-24 Hemmstoff für die gefässneubildung, der den gewebefaktor-inhibitor (tfpi) enthält Expired - Fee Related DE69726281T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP9617696 1996-03-25
JP9617696 1996-03-25
PCT/JP1997/000973 WO1997035609A1 (fr) 1996-03-25 1997-03-24 Inhibiteur de la neoformation de vaisseaux sanguins renfermant un inhibiteur du mecanisme d'action du facteur tissulaire

Publications (2)

Publication Number Publication Date
DE69726281D1 true DE69726281D1 (de) 2003-12-24
DE69726281T2 DE69726281T2 (de) 2004-08-26

Family

ID=14158025

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69726281T Expired - Fee Related DE69726281T2 (de) 1996-03-25 1997-03-24 Hemmstoff für die gefässneubildung, der den gewebefaktor-inhibitor (tfpi) enthält

Country Status (9)

Country Link
US (1) US6060449A (de)
EP (1) EP0914830B1 (de)
JP (1) JP4129994B2 (de)
KR (1) KR100442758B1 (de)
AT (1) ATE254472T1 (de)
AU (1) AU706582B2 (de)
CA (1) CA2250008A1 (de)
DE (1) DE69726281T2 (de)
WO (1) WO1997035609A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0912549A4 (de) 1996-06-20 2002-01-02 Univ Texas Verbindungen und verfahren zur bereitstellung aktiver zubereitungen und deren verwendung
US6946439B2 (en) 1997-02-06 2005-09-20 Entre Med, Inc. Compositions and methods for inhibiting cellular proliferation comprising TFPI fragments
ATE429643T1 (de) 2000-07-12 2009-05-15 Agensys Inc Neues tumor antigen das für diagnose und therapie von blasen-, eierstock-, lungen- und nierenkrebs verwendet werden kann
KR20050036867A (ko) 2001-10-15 2005-04-20 카이론 코포레이션 조직인자경로 억제제（ｔｆｐｉ）의 투여에 의한 중증폐렴의 치료
EP1729791A2 (de) * 2004-03-17 2006-12-13 Chiron Corporation Behandlung schwerer, ambulant erworbener pneumonie mittels verabreichung des gewebefaktorinhibitors (tfpi)
JP2009538317A (ja) 2006-05-26 2009-11-05 バイエル ヘルスケア リミティド ライアビリティ カンパニー 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ
EP2134677B1 (de) 2006-12-20 2011-10-12 Bayer HealthCare LLC 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl)phenyl]-1h-pyrazol-5-yl}carbamoyl)-amino]-3-chlorophenoxy}-n-methylpyridin-2-carboxamid als inhibitor der vegfr kinase zur behandlung von krebs
WO2010107991A2 (en) * 2009-03-18 2010-09-23 Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Use of ixolaris, a tissue factor inhibitor, for the treatment and prevention of cancer
ES2621809T3 (es) 2010-03-19 2017-07-05 Baxalta GmbH Inhibidores de TFPI y procedimientos de uso
CN103079567A (zh) 2010-04-17 2013-05-01 拜尔健康护理有限责任公司 用于疾病和病症的治疗和预防的氟取代的ω-羧基芳基二苯脲的合成代谢产物
WO2012012404A1 (en) 2010-07-19 2012-01-26 Bayer Healthcare Llc Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5276015A (en) * 1992-03-18 1994-01-04 Washington University Method of inhibiting microvascular thrombosis
JP3428687B2 (ja) * 1993-06-30 2003-07-22 財団法人化学及血清療法研究所 組織因子凝固系インヒビターの調製法
US5902582A (en) * 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
US5981471A (en) * 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation

Also Published As

Publication number Publication date
EP0914830B1 (de) 2003-11-19
WO1997035609A1 (fr) 1997-10-02
CA2250008A1 (en) 1997-10-02
ATE254472T1 (de) 2003-12-15
AU706582B2 (en) 1999-06-17
US6060449A (en) 2000-05-09
DE69726281T2 (de) 2004-08-26
EP0914830A1 (de) 1999-05-12
AU1944997A (en) 1997-10-17
KR19990087825A (ko) 1999-12-27
KR100442758B1 (ko) 2004-10-06
EP0914830A4 (de) 2002-03-20
JP4129994B2 (ja) 2008-08-06

Similar Documents

Publication Publication Date Title
SE8503680L (sv) Indolderivat
EP0906307A4 (de) Substituierte imidazole mit cytokinin-inhibirender wirkung
EA199800268A1 (ru) Замещенные имидазолы, обладающие антиканцерогенной и цитокин-ингибирующей активностью
TNSN94105A1 (fr) Composes sulfonamides tricycliques utiles pour l'inhibition de la fonction proteine g et pour le traitement des maladies proliferatives
DE3774918D1 (de) Cancerostatisches mittel.
CA2260777A1 (en) Pentafluorobenzenesulfonamides and analogs
ES2152414T3 (es) Dihidrobenzofuranos.
DE59409312D1 (de) Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten
DE69030476D1 (de) Verwendung von Protease-Inhibitoren als antiexudative, antiphlogistische und antimikrobielle Mittel
DE69726281D1 (de) Hemmstoff für die gefässneubildung, der den gewebefaktor-inhibitor (tfpi) enthält
ATE79031T1 (de) Verwendung von ketonderivaten zur behandlung von depressionen.
DE69720542D1 (de) PYRIDOCARBAZOL DERIVATE DIE EINEN cGMP-PDE INHIBILIERENDEN EFFEKT HABEN
GB8925833D0 (en) Derivatives of aromatic benzoates as inhibitors of esterase-producing micro-organisms
MD502G2 (ro) Derivaţi noi ai adenozinei, procedee de preparare a lor, compoziţii farmaceutice ce le conţin
ATE266027T1 (de) Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten
FR2722689B1 (fr) Nouveau produit de combinaison comprenant un agent antifongique et du crotamiton comme potentialisateur de l'activite de l'agent antifongique, et compositions dermatologiques et/ou cosmetiques le comprenant
TW325472B (en) A pharmaceutical composition for preventing cancer comprising 2-(1-hydroxyethyl)-5-hydroxynaphto[2,3-b]furan-4,9-dione
SE9802538D0 (sv) New pharmaceutically active compounds
EA199800033A1 (ru) Антагонисты канала кальция
ATE190845T1 (de) Rektale flunisolid-zubereitung zur behandlung entzündlicher darmerkrankungen
NO903585L (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1,3-oksaziner.
SE9902596D0 (sv) Pharmaceutically active compounds
CA2257200A1 (en) Substituted imidazoles having cytokine inhibitory activity
UA31283A (uk) Спосіб вилучення пухлини зорового нерву орбітальної локалізації

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee